PARP-Inhibitor unabhängig von BRCA-Mutationsstatus zugelassen
Crossref DOI link: https://doi.org/10.1007/s15015-017-3725-9
Published Online: 2017-12-16
Published Print: 2017-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
red,
